¿¢¼ÒÁ» ¿ä¹ý ½ÃÀå : Ä¡·á À¯Çüº°, ÀûÀÀÁõº°, Ä¡·á ¿µ¿ªº°, Åõ¿© °æ·Îº°, Áö¿ªº° - ¾÷°è µ¿Çâ°ú ¼¼°è ¿¹Ãø(-2035³â)
Exosome Therapy Market by Type of Therapeutic, Target Indication, Therapeutic Area, Route of Administration and Geography : Industry Trends and Global Forecasts, Till 2035
»óǰÄÚµå : 1648562
¸®¼­Ä¡»ç : Roots Analysis
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 190 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,799 £Ü 6,810,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,999 £Ü 9,932,000
PDF (One-Location Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ Æ¯Á¤ »ç¾÷ ºÎ¹®¿¡ ¼ÓÇÑ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,599 £Ü 15,041,000
PDF (Department License) help
PDF º¸°í¼­¸¦ ºÎ¼­ ´ÜÀ§·Î 12¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,999 £Ü 25,542,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¿¢¼ÒÁ» ¿ä¹ý ½ÃÀå ±Ô¸ð´Â 2029³â 3,000¸¸ ´Þ·¯¿¡¼­ 2040³â¿¡´Â 14¾ï ´Þ·¯·Î ¼ºÀåÇϸç, 2035³â±îÁöÀÇ ¿¹Ãø ±â°£ Áß CAGR 41.1%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¶Á÷ Àç»ý ÃËÁø, ¿°Áõ ¹× ¸¸¼º ÅëÁõ ¿ÏÈ­, Ç¥Àû ƯÀ̼º µî ´Ù¾çÇÑ ÀåÁ¡À¸·Î ÀÎÇØ ÃÖ±Ù ¿¢¼Ø ¿ä¹ýÀÌ Å« ÁÖ¸ñÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ¿¬±¸¸¦ ÅëÇØ ¿¢¼ÒÁ» Ä¡·áÁ¦ÀÇ Áúº´ Áø´Ü, ¾à¹°Àü´Þ, Ä¡·á Àû¿ë¿¡ ÀÖÀ¸¸ç, ³ôÀº È¿´É°ú Ä¡·áÀû ¿ì¿ù¼ºÀÌ ÀÔÁõµÇ°í ÀÖ½À´Ï´Ù. ÇöÀç Àü ¼¼°è¿¡¼­ 120°³ ÀÌ»óÀÇ Ä¡·áÁ¦ Èĺ¸¹°ÁúÀÌ ¼ö¸¹Àº Áúº´ ÀûÀÀÁõ¿¡ ´ëÇÑ Ä¡·á¸¦ À§ÇØ ¿¬±¸µÇ°í ÀÖ´Ù´Â Á¡Àº ÁÖ¸ñÇÒ ¸¸ÇÕ´Ï´Ù. ÀÌ´Â ÀÌ ºÐ¾ß¿¡¼­ Á¦¾àȸ»çµéÀÇ ±¤¹üÀ§ÇÑ °³¹ß ³ë·ÂÀÌ ÀÌ·ç¾îÁö°í ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù. ÀüüÀÇ 40% ÀÌ»óÀÌ ´Ù¾çÇÑ ÀÓ»ó °³¹ß ´Ü°è¿¡ ÀÖ½À´Ï´Ù. Àüü Èĺ¸¹°Áú Áß EXOMSC-COV19(Dermama Biotech Lab), Dex2(Gustave Roussy Institute), SF-MSC-EX(Osmangazi University)¸¦ Æ÷ÇÔÇÑ 7°³ÀÇ ¿¢¼ÒÁ» Ä¡·áÁ¦°¡ ÇöÀç °³¹ßÀÇ °í±Þ ÀÓ»ó´Ü°è¿¡¼­ ½ÃÇè ÁßÀÔ´Ï´Ù.

ÇöÀç ¿¢¼ÒÁ»À» ÀÌ¿ëÇÑ Ä¡·áÁ¦ÀÇ ¾à 30%°¡ ´Ù¾çÇÑ ¾Ï Ä¡·áÁ¦·Î °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ Á¢±Ù¹ýÀº ¿¢¼ÒÁ»À» ¾Ï¼¼Æ÷¿¡ ƯÀÌÀûÀ¸·Î ¾à¹°À» Àü´ÞÇÏ´Â ¼ö´ÜÀ¸·Î »ç¿ëÇÏ´Â °ÍÀ¸·Î, ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ¾ÆÁ÷ ¿¬±¸ Ãʱ⠴ܰ迡 ÀÖ½À´Ï´Ù. ¿¢¼ÒÁ» Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇØ ¿¬±¸µÇ°í ÀÖ´Â ÁÖ¿ä ¾ÏÁ¾À¸·Î´Â À¯¹æ¾Ï, Æó¾Ï, Èæ»öÁ¾, ´ëÀå¾Ï µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß¿¡¼­ ÁøÇà ÁßÀÎ ¿¬±¸°³¹ß ³ë·Â, À¯¸ÁÇÑ ÀÓ»ó½ÃÇè °á°ú, Èı⠿¢¼ÒÁ» Ä¡·áÁ¦ÀÇ Ãâ½Ã µîÀ» °í·ÁÇÒ ¶§, ÇâÈÄ 10³â°£ ÀÌ ½ÃÀåÀº °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü ¼¼°è 60¿©°³ ±â¾÷ÀÌ ¿¢¼ÒÁ» Ä¡·áÁ¦ °³¹ß¿¡ Âø¼öÇϰí ÀÖÀ¸¸ç, ½ºÅ¸Æ®¾÷°ú ¼Ò±Ô¸ð ±â¾÷ÀÇ Á¸Àç°¡ ½ÃÀå Æ¯Â¡ÀÔ´Ï´Ù.

Exosome Therapy Market-IMG1

¿¢¼ÒÁ» °ü·Ã Ä¡·á¹ý ¹× ¹ÙÀÌ¿À¸¶Ä¿¸¦ Æò°¡ÇÏ´Â ÀÓ»ó½ÃÇè¿¡´Â ´Ù¾çÇÑ Áö¿ª¿¡¼­ 3,000¸í ÀÌ»óÀÇ È¯ÀÚ°¡ ¸ðÁý/µî·ÏµÇ¾î ÀÖ½À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ¿¢¼ÒÁ» Ä¡·áÁ¦ ¿¬±¸°³¹ßÀ» À§ÇØ 530°³ ÀÌ»óÀÇ º¸Á¶±ÝÀÌ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ÀåÁ¡°ú ¹Ì·¡ °¡´É¼ºÀ» ¾Ë¾Æº» ´Ù¾çÇÑ ÅõÀÚÀÚµéÀÌ 30°³ ÀÌ»óÀÇ »ç·Ê¿¡ 5¾ï 7,000¸¸ ´Þ·¯ ÀÌ»óÀ» ÅõÀÚÇß½À´Ï´Ù.

ÇöÀç ÀÌ ºÐ¾ß´Â 30°³ ÀÌ»óÀÇ ½ºÅ¸Æ®¾÷ÀÌ Çõ½ÅÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, ÃÖ±Ù ¼ö³â°£ ¿¢¼ÒÁ» Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ ´Ù¾çÇÑ R&D ±¸»óÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

Exosome Therapy Market-IMG2

¼¼°èÀÇ ¿¢¼ÒÁ» ¿ä¹ý ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀåÀÇ °³¿ä¿Í Ä¡·á À¯Çüº°, ÀûÀÀÁõº°, Ä¡·á ¿µ¿ªº°, Åõ¿© °æ·Îº°, Áö¿ªº° µ¿Çâ ¹× ½ÃÀå¿¡ Âü¿©ÇÏ´Â ±â¾÷ÀÇ °³¿ä µîÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °³¿ä

Á¦3Àå ¼­·Ð

Á¦4Àå ¿¢¼ÒÁ» Ä¡·áÁ¦ : ½ÃÀå ±¸µµ

Á¦5Àå ¿¢¼ÒÁ» Ä¡·áÁ¦ °³¹ß ±â¾÷ : ±â¾÷ °³¿ä

Á¦6Àå ¿¢¼ÒÁ» Ä¡·áÁ¦ : ¾àÁ¦ °³¿ä

Á¦7Àå ÀÓ»ó½ÃÇèÀÇ ºÐ¼®

Á¦8Àå Çмú º¸Á¶±ÝÀÇ ºÐ¼®

Á¦9Àå ¼¼°è À̺¥Æ® ºÐ¼®

Á¦10Àå ÆÄÆ®³Ê½Ê°ú Çù¾÷

Á¦11Àå ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ ºÐ¼®

Á¦12Àå ½ºÅ¸Æ®¾÷ °Ç°­ ÁöÇ¥

Á¦13Àå »ç·Ê ¿¬±¸ : ¿¢¼ÒÁ» °³¹ß ¹× Á¦Á¶ ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ

Á¦14Àå ¾àÁ¦ ½ÇÆÐÀÇ ºÐ¼®

Á¦15Àå ½ÃÀå ±Ô¸ðÀÇ Æò°¡¿Í ±âȸ ºÐ¼®

Á¦16Àå À̱×Á¦Å¥Æ¼ºê ÀλçÀÌÆ®

Á¦17Àå ºÎ·Ï 1 : Ç¥ Çü½Ä µ¥ÀÌÅÍ

Á¦18Àå ºÎ·Ï 2 : ±â¾÷¡¤´Üü ¸®½ºÆ®

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

EXOSOME THERAPY MARKET: OVERVIEW

As per Roots Analysis, the global exosome therapy is estimated to grow from USD 0.03 billion in 2029 to USD 1.4 billion by 2040, at a CAGR of 41.1% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Exosome Therapeutics

Target Disease Indications

Therapeutic Area

Route of Administration

Key Geographical Regions

EXOSOME THERAPY MARKET: GROWTH AND TRENDS

Owing to the various benefits, such as enhanced tissue regeneration, reduced inflammation and chronic pain, and target specificity, exosome therapies have garnered significant attention in the recent past. Various studies have demonstrated the high efficacy and therapeutic superiority of exosome therapeutics in disease diagnosis, drug delivery and therapeutic applications. It is worth highlighting that over 120 therapeutic candidates are currently being investigated for treating myriads of disease indications, across the globe. This depicts the extensive development efforts being undertaken by drug developers in this domain. More than 40% of the total number of drugs are in various phases of clinical development. Of the total candidates, seven exosome therapies, including EXOMSC-COV19 (Dermama Biotech Lab), Dex2 (Gustave Roussy Institute), SF-MSC-EX (Osmangazi University), are currently being tested in the advanced clinical stages of development.

At present, around 30% of exosome-based therapeutics are under development for the treatment of various cancers. This innovative approach uses exosomes as a means to deliver drugs specifically to cancer cells, and these therapies are still in the early phases of research. Notable types of cancer being investigated for exosome delivery systems include breast cancer, lung cancer, melanoma, and colon cancer. Considering the ongoing R&D efforts in this domain, promising clinical trial results and anticipated launch of late-stage exosome therapies, the market is anticipated to witness notable growth over the next decade.

EXOSOME THERAPY MARKET: KEY INSIGHTS

The report delves into the current state of the exosome therapy market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Exosome Therapy Market - IMG1
Exosome Therapy Market - IMG2

EXOSOME THERAPY MARKET: KEY SEGMENTS

Autologous Therapies are Likely to Capture Largest Share of the Exosome Therapy Market

Based on the type of therapy, the market is segmented into allogenic therapy and autologous therapy. It is anticipated that the autologous therapy segment will hold the maximum share of the exosome therapy market in 2029. However, it is worth highlighting that allogeneic therapy is likely to grow at a relatively higher CAGR.

Retinitis Pigmentosa is Likely to be the Fastest Growing Segment of the Exosome Therapy Market During the Forecast Period

Based on the target disease indication, the market is segmented into degenerative meniscal injury, dystrophic epidermolysis bullosa, fistula perianal and retinitis pigmentosa. It is anticipated that fistula perianal will hold the maximum share of the exosome therapy market in 2029. However, it is worth highlighting that the exosome therapy market for retinitis pigmentosa is likely to grow at a relatively higher CAGR.

Rectal Disorders Segment is the Fastest Growing Segment of the Exosome Therapy Market

Based on the therapeutic area, the market is segmented into dermatological disorders, musculoskeletal disorders, ophthalmic disorders and rectal disorders. While the rectal disorders segment is likely to hold a relatively higher market share, it is worth highlighting that the ophthalmic diseases segment is expected to witness substantial market growth in the coming years.

Fistula Tract Segment is Likely to Capture Largest Share of the Exosome Therapy Market in 2029

Based on the route of administration, the market is segmented into fistula tract, intra-articular and intra-ocular. It is anticipated that the fistula tract segment will hold the maximum share of the exosome therapy market in 2029. However, it is worth highlighting that the intraocular segment is likely to grow at a relatively higher CAGR.

Asia-Pacific Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and the Rest of the World. The majority share is expected to be captured by drug developers based in Asia-Pacific. It is worth highlighting that, over the years, the market in Europe is expected to grow at a higher CAGR.

Example Players in the Exosome Therapy Market

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

EXOSOME THERAPY MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE

5. EXOSOME THERAPEUTICS DEVELOPERS: COMPANY PROFILES

6. EXOSOME THERAPEUTICS: DRUG PROFILES

7. CLINICAL TRIAL ANALYSIS

8. ACADEMIC GRANT ANALYSIS

9. GLOBAL EVENT ANALYSIS

10. PARTNERSHIPS AND COLLABORATIONS

11. FUNDING AND INVESTMENT ANALYSIS

12. START-UP HEALTH INDEXING

13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS

14. DRUG FAILURE ANALYSIS

15. MARKET SIZING AND OPPORTUNITY ANALYSIS

16. EXECUTIVE INSIGHTS

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â